全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

Efficacy of Bevacizumab versus Epidermal Growth Factor Receptor Inhibitors for Ras Wild Type Metastatic Colorectal Cancer: A Real-World Data Analysis from a Tertiary Care Institution

DOI: 10.4236/oalib.1109293, PP. 1-7

Subject Areas: Oncology

Keywords: Colorectal Cancer, Advanced Disease, First-line, Biologics, Survival

Full-Text   Cite this paper   Add to My Lib

Abstract

Introduction: A combination of chemotherapy regimen and biologics in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) resulted in improvements in survival. However, the optimal choice of initial biologic therapy in previously untreated patients remains challenging. Aim: The objective of this study is to compare the efficacy and safety outcomes of first-line epidermal growth factor receptor (EGFR) inhibitors versus vascular endothelial growth factor (VEGF) inhibitors in patients with RAS wtmCRC. Methods: A retrospective analytical study of patients with RAS wtmCRC who received first-line chemotherapy with either bevacizumab or panitumumab/cetuximab was conducted at the department of medical oncology of Hassan II University Hospital of Fez, Morocco, over a period of 4 years (June 2015 to June 2019). Endpoints included overall survival (OS), progression-free survival (PFS) and overall response rate (ORR). Results: 85 patients were included: 48.2% (n = 41) received cetuximab or panitumumab and 51.7% (n = 44) received bevacizumab, in association with first-line chemotherapy. Median OS and PFS did not differ significantly between patients having received bevacizumab and cetuximab or panitumumab treatment. ORR was significantly higher with first-line treatment with EGFRi. The proportion of patients with treatment-related grade 3 or higher, adverse events was similar between treatment groups. Conclusion: Our study showed no significant difference in survival between the addition of cetuximab/panitumumab vs bevacizumab to first-line chemotherapy as initial biologic treatment in RAS-wt mCRC patients.

Cite this paper

Amaadour, L. , Berrad, S. , Harch, I. E. , Oualla, K. , Arifi, S. , Ghazi, K. E. , Chbani, L. , Benbrahim, Z. and Mellas, N. (2023). Efficacy of Bevacizumab versus Epidermal Growth Factor Receptor Inhibitors for Ras Wild Type Metastatic Colorectal Cancer: A Real-World Data Analysis from a Tertiary Care Institution. Open Access Library Journal, 10, e9293. doi: http://dx.doi.org/10.4236/oalib.1109293.

References

[1]  Xie, Y.H., Chen, Y.X. and Fang, J.Y. (2020) Comprehensive Review of Targeted Therapy for Colorectal Cancer. Signal Transduction and Targeted Therapy, 5, Article No. 22. https://doi.org/10.1038/s41392-020-0116-z
[2]  Zhou, M., Yu, P., Qu, J., Chen, Y., Zhou, Y., Fu, L. and Zhang, J. (2016) Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis. Cellular Physiology and Biochemistry, 40, 361-369. https://doi.org/10.1159/000452551
[3]  Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., et al. (2008) K-Ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. The New England Journal of Medicine, 359, 1757-1765. https://doi.org/10.1056/NEJMoa0804385
[4]  Sorich, M.J., Wiese, M.D., Rowland, A., Kichenadasse, G., McKinnon, R.A. and Karapetis, C.S. (2015) Extended RAS Mutations and Anti-EGFR Monoclonal Antibody Survival Benefit in Metastatic Colorectal Cancer: A Meta-Analysis of Randomized, Controlled Trials. Annals of Oncology, 26, 13-21. https://doi.org/10.1093/annonc/mdu378
[5]  Hurwitz, H.I., Tebbutt, N.C., Kabbinavar, F., Giantonio, B.J., et al. (2013) Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis from Seven Randomized Controlled Trials. The Oncologist, 18, 1004-1012. https://doi.org/10.1634/theoncologist.2013-0107
[6]  Ducreux, M., Adenis, A., Pignon, J.P., et al. (2013) Efficacy and Safety of Bevacizumab-Based Combination Regimens in Patients with Previously Untreated Metastatic Colorectal Cancer: Final Results from a Randomised Phase II Study of Bevacizumab Plus 5-Fluorouracil, Leucovorin Plus Irinotecan versus Bevacizumab Plus Capecitabine Plus Irinotecan (FNCLCC ACCORD 13/0503 Study). European Journal of Cancer, 49, 1236-1245. https://doi.org/10.1016/j.ejca.2012.12.011
[7]  Douillard, J.Y., Oliner, K.S., Siena, S., et al. (2015) Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. The New England Journal of Medicine, 369, 1023-1034. https://doi.org/10.1056/NEJMoa1305275
[8]  Heinemann, V., von Weikersthal, L.F., Decker, T., et al. (2014) FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer (FIRE-3). The Lancet Oncology, 15, 1065-1075. https://doi.org/10.1016/S1470-2045(14)70330-4
[9]  Venook, A.P., Niedzwiecki, D., Lenz, H.-J., et al. (2014) CALGB/SWOG 80405: Phase III Trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxali-platin/5-FU/leucovorin (mFOLFOX6) with Bevacizumab or Cetuximab for Patients with KRAS Wild-Type Untreated Metastatic Adenocarcinoma of the Colon or Rectum. Journal of Clinical Oncology, 32, No. 18. https://doi.org/10.1200/jco.2014.32.18_suppl.lba3
[10]  Schwartzberg, L.S., Rivera, F., Karthaus, M., et al. (2014) PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin-(mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients with Previously Treated Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer. Journal of Clinical Oncology, 32, 2240-2247. https://doi.org/10.1200/JCO.2013.53.2473
[11]  Holch, J.W., Ricard, I., Stintzing, S., Modest, D.P. and Heinemann, V. (2017) The Relevance of Primary Tumour Location in Patients with Metastatic Colorectal Cancer: A Meta-Analysis of First-Line Clinical Trials. European Journal of Cancer, 70, 87-98. https://doi.org/10.1016/j.ejca.2016.10.007

Full-Text


comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413